Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.

European journal of cancer (Oxford, England : 1990) - 1 Aug 2015

Croce Sabrina, Chibon Frédéric

Abstract excerpt

MED12 is a subunit of the multiprotein complex Mediator, an evolutionary-conserved regulator of transcription. Oncogenic mutations in exon 2 of MED12 occur in nearly 70% of uterine leiomyomas, and together with HMGA, represent the most common genetic anomalies in leiomyoma. This mutational anomaly represents a driver mutation. MED12 mutations are restricted to benign smooth muscle tumours (leiomyomas) of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinogenesis
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to Leiomyoma

Share to Leiomyosarcoma

Share to Mediator Complex

Share to Uterine Neoplasms

Source

Identifiers

PMID: 26037152
DOI: 10.1016/j.ejca.2015.04.023

Genes

MED12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.PMID 26037152Read ↗

MED12 mutations in leiomyosarcoma and extrauterine leiomyoma.Semantic proximity Read ↗

MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors.Semantic proximity Read ↗

MED12 alterations in both human benign and malignant uterine soft tissue tumors.Semantic proximity Read ↗

Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.Semantic proximity Read ↗

The Mediator Complex Subunit 12 (MED-12) Gene and Uterine Fibroids: a Systematic Review.Semantic proximity Read ↗

Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyomaSemantic proximity Read ↗

Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.Semantic proximity Read ↗

MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.Semantic proximity Read ↗

MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.Semantic proximity Read ↗

Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.Semantic proximity Read ↗

Med12 gain-of-function mutation causes leiomyomas and genomic instabilitySemantic proximity Read ↗

MED12 dysregulation: insights into cancer and therapeutic resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.